用于监测厄洛替尼治疗的非小细胞肺癌疗效的（18）F-FDG-PET/CT上的肿瘤异质性
Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib.
作者信息
van Gool Matthijs H, Aukema Tjeerd S, Sinaasappel Michiel, Valdés Olmos Renato A, Klomp Houke M
机构信息
1 Department of Surgical Oncology, 2 Department of Nuclear Medicine, 3 Department of Physics, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
出版信息
J Thorac Dis. 2016 Mar;8(3):E200-3. doi: 10.21037/jtd.2016.02.10.
Abstract
Response monitoring using fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography (FDG-PET/CT) textural features has potential in targeted treatment with erlotinib in non-small cell lung cancer (NSCLC) patients. Patients with substantial decrease of metabolic activity during erlotinib treatment will probably benefit from continued treatment. However, various aspects of the method (quantification tools, cut-off values, etc.) need to be standardized before the software becomes widely available in a similar manner as standardized uptake value (SUV) measurements. Heterogeneity on FDG-PET/CT opened an additional window for innovation but simultaneously a new challenge for molecular hybrid imaging.
摘要
使用与低剂量计算机断层扫描（FDG-PET/CT）纹理特征一起采集的氟脱氧葡萄糖正电子发射断层扫描进行反应监测，在非小细胞肺癌（NSCLC）患者中使用厄洛替尼进行靶向治疗具有潜力。在厄洛替尼治疗期间代谢活性大幅下降的患者可能会从持续治疗中获益。然而，在该软件以与标准化摄取值（SUV）测量类似的方式广泛可用之前，该方法的各个方面（量化工具、临界值等）需要标准化。FDG-PET/CT上的异质性为创新打开了一个额外的窗口，但同时也给分子混合成像带来了新的挑战。
相似文献
1
Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib.用于监测厄洛替尼治疗的非小细胞肺癌疗效的（18）F-FDG-PET/CT上的肿瘤异质性
J Thorac Dis. 2016 Mar;8(3):E200-3. doi: 10.21037/jtd.2016.02.10.
2
(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.（18）18F-氟脱氧葡萄糖正电子发射断层扫描与计算机断层扫描在预测可切除非小细胞肺癌对表皮生长因子受体-酪氨酸激酶抑制剂治疗的组织病理学反应中的比较
Ann Surg Oncol. 2014 Sep;21(9):2831-7. doi: 10.1245/s10434-014-3791-6. Epub 2014 May 21.
3
FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.非小细胞肺癌患者接受表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗期间的氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）反应评估
World J Radiol. 2014 Jul 28;6(7):392-8. doi: 10.4329/wjr.v6.i7.392.
4
Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.肿瘤内18F-FDG摄取异质性降低了正电子发射断层扫描/计算机断层扫描成像在靶体积定义上的可靠性。
J Med Imaging Radiat Oncol. 2015 Jun;59(3):338-45. doi: 10.1111/1754-9485.12289. Epub 2015 Feb 23.
5
Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.对于非小细胞肺癌患者，3'-脱氧-3'-(18)F-氟胸苷或2'-脱氧-2'-(18)F-氟-D-葡萄糖PET/CT能否更好地评估表皮生长因子受体激酶抑制剂治疗3周后的疗效？初步结果。
Hell J Nucl Med. 2014 May-Aug;17(2):90-6. doi: 10.1967/s002449910136. Epub 2014 Jul 5.
6
CD147-mediated glucose metabolic regulation contributes to the predictive role of F-FDG PET/CT imaging for EGFR-TKI treatment sensitivity in NSCLC.CD147 介导的葡萄糖代谢调控有助于 F-FDG PET/CT 成像预测 NSCLC 患者对 EGFR-TKI 治疗敏感性的作用。
Mol Carcinog. 2019 Feb;58(2):247-257. doi: 10.1002/mc.22923. Epub 2018 Oct 25.
7
Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.(18)F-FDG-PET/CT 的标准化摄取值可预测 EGFR-TKI 获得性耐药患者中 EGFR T790M 突变状态。
Lung Cancer. 2016 Oct;100:14-19. doi: 10.1016/j.lungcan.2016.07.022. Epub 2016 Jul 22.
8
Assessment of pulmonary F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib.对接受放疗和厄洛替尼治疗的非小细胞肺癌患者肺部 F-FDG-PET 摄取及细胞因子谱的评估。
Clin Transl Radiat Oncol. 2017 Jun 15;4:57-63. doi: 10.1016/j.ctro.2017.04.002. eCollection 2017 Jun.
9
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.使用 18F-FDG 和 3'-脱氧-3'-18F-氟胸苷 PET 对晚期非小细胞肺癌厄洛替尼治疗反应的定量分析。
J Nucl Med. 2011 Dec;52(12):1871-7. doi: 10.2967/jnumed.111.094458. Epub 2011 Nov 7.
10
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.3'-去氧-3'-18F-氟代胸苷 PET/CT 引导表皮生长因子受体拮抗剂和 Bcl-xL 抑制剂治疗非小细胞肺癌。
J Nucl Med. 2012 Mar;53(3):443-50. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13.
引用本文的文献
1
Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.纳入治疗前18F-FDG PET的影像组学特征可改善EGFR突变型肺腺癌患者的生存分层。
PLoS One. 2020 Dec 28;15(12):e0244502. doi: 10.1371/journal.pone.0244502. eCollection 2020.
2
Combining structural and textural assessments of volumetric FDG-PET uptake in NSCLC.结合非小细胞肺癌中体积性氟代脱氧葡萄糖正电子发射断层扫描摄取的结构和纹理评估。
IEEE Trans Radiat Plasma Med Sci. 2019 Jul;3(4):421-433. doi: 10.1109/trpms.2019.2912433. Epub 2019 Apr 24.
3
Predictive Power of a Radiomic Signature Based on F-FDG PET/CT Images for EGFR Mutational Status in NSCLC.基于F-FDG PET/CT图像的放射组学特征对非小细胞肺癌EGFR突变状态的预测能力
Front Oncol. 2019 Oct 15;9:1062. doi: 10.3389/fonc.2019.01062. eCollection 2019.
4
Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.非小细胞肺癌患者治疗前PET显示的瘤内异质性可预测表皮生长因子受体酪氨酸激酶抑制剂治疗的无进展生存期。
PLoS One. 2018 Jan 31;13(1):e0189766. doi: 10.1371/journal.pone.0189766. eCollection 2018.
5
Clinical applications of textural analysis in non-small cell lung cancer.纹理分析在非小细胞肺癌中的临床应用
Br J Radiol. 2018 Jan;91(1081):20170267. doi: 10.1259/bjr.20170267. Epub 2017 Oct 27.
本文引用的文献
1
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.IV期非小细胞肺癌的全身治疗：美国临床肿瘤学会临床实践指南更新
J Clin Oncol. 2015 Oct 20;33(30):3488-515. doi: 10.1200/JCO.2015.62.1342. Epub 2015 Aug 31.
2
Comparison of FDG-PET/CT images between chronic renal failure patients on hemodialysis and controls.血液透析慢性肾衰竭患者与对照组之间的氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描（FDG-PET/CT）图像比较。
Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):204-11. eCollection 2015.
3
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌：PET 摄取（18）F-FDG 的异质性与治疗反应和预后的关系。
Radiology. 2015 Sep;276(3):883-93. doi: 10.1148/radiol.2015141309. Epub 2015 Apr 17.
4
PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer.正电子发射断层显像-计算机断层扫描用于评估疑似可切除非小细胞肺癌患者的纵隔淋巴结受累情况。
Cochrane Database Syst Rev. 2014 Nov 13;2014(11):CD009519. doi: 10.1002/14651858.CD009519.pub2.
5
FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.非小细胞肺癌患者接受表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗期间的氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）反应评估
World J Radiol. 2014 Jul 28;6(7):392-8. doi: 10.4329/wjr.v6.i7.392.
6
Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.厄洛替尼治疗非小细胞肺癌时代谢反应监测的时机。
J Nucl Med. 2014 Jul;55(7):1081-6. doi: 10.2967/jnumed.113.130674. Epub 2014 May 8.
7
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.肿瘤病灶糖酵解与肿瘤病灶增殖用于预测接受厄洛替尼治疗的晚期非小细胞肺癌患者的疗效和预后差异。
Clin Nucl Med. 2012 Nov;37(11):1058-64. doi: 10.1097/RLU.0b013e3182639747.
8
Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.早期非小细胞肺癌患者新辅助厄洛替尼的肿瘤反应和毒性。
J Clin Oncol. 2012 Aug 1;30(22):2731-8. doi: 10.1200/JCO.2011.39.4882. Epub 2012 Jul 2.
9
Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET.基于 18F-FDG PET 的纹理特征分析评估肿瘤摄取异质性的可重复性。
J Nucl Med. 2012 May;53(5):693-700. doi: 10.2967/jnumed.111.099127. Epub 2012 Mar 27.
10
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
Zotero 插件